Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review - Wikidata - wikimedia - TriplyDB

Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review

Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review

http://www.wikidata.org/entity/Q35584543

about

Vascular Complications of Cancer Chemotherapy Toward a Cancer Drug of Fungal Origin Therapeutic manipulation of angiogenesis with miR-27b Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets Consumptive coagulopathy in angiosarcoma: a recurrent phenomenon?Tumor control versus adverse events with targeted anticancer therapies.What the emergency radiologist needs to know about treatment-related complications from conventional chemotherapy and newer molecular targeted agents.Thromboembolic disease in cancer patients.Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy.Arterial hypertension and cancer.Do anti-angiogenic cancer therapies increase risk of significant weight loss?Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer.The adverse effects of sorafenib in patients with advanced cancers.Risk of gastrointestinal events with newly approved (after 2011) vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials.The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation.Nonclinical safety biomarkers of drug-induced vascular injury: current status and blueprint for the future.The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis.The value of [11C]-acetate PET and [18F]-FDG PET in hepatocellular carcinoma before and after treatment with transarterial chemoembolization and bevacizumab.Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer Quantifying the relationship between inhibition of VEGFR-2, drug-induced blood pressure elevation and hypertension.Atypical reversible posterior leukoencephalopathy syndrome (RPLS) induced by cediranib in a patient with metastatic rectal cancer.Efficacy and safety of targeting VEGFR drugs in treatment for advanced or metastatic gastric cancer: a systemic review and meta-analysis.

P2860

Q26766269-9EE2F568-4C2F-470D-83D0-A360C8C496B6 Q35596957-25C80123-0F05-4577-AEDB-A0E18EE739E8 Q35835060-13B0DFD9-48B5-4D50-943C-B7422D8DB8A3 Q36158922-7809ABD2-DD42-4F34-B8F9-A3EF85660B5C Q37622856-49BCCAD6-2FC2-4FC1-B0A5-A9961CAD7247 Q37969899-42CF8C1D-79FD-4CB6-9BEB-5F2BA73415AD Q38016741-5E6EE72C-0C04-46D4-9454-CB6FFCDEE342 Q38083556-3DC79626-56D5-4655-B335-628F9B4D8E4C Q38101883-AE09DC69-9374-404D-B4A8-82F22EB6E976 Q38101885-11156C81-2A63-4971-BE47-FE38CE99AC4E Q38115762-B42EA5D9-1A7C-43B3-9454-8F90B511F60C Q38192670-68F2FA4D-A297-49CE-82FE-377868AF1715 Q38225636-A32F4783-27FF-420E-8D93-592BF286B167 Q38286308-106BF7F8-F7FD-4660-B437-D44AFAAD4BC5 Q38678038-8C3415A7-3EF4-472B-BF2F-0E9C22803E46 Q38925714-881D96AB-C140-4404-B05B-563EB58B3D05 Q39201920-729C6FE4-B4CE-435B-948F-6E9B692ECA6F Q39344375-C1B2E16E-738E-4F37-80FF-3539F6B4612B Q41192134-DC609579-B5A5-45BA-9347-ED52053354EA Q41947800-552EAC9C-5F13-45EB-846A-432798EF00B1 Q47434764-1EDD1D87-E539-403B-B8CE-C163775530B5 Q48774492-5D2841DF-AD27-4731-BBD3-DF8EBF0456C7 Q52682256-386FC8C5-C8FE-4B2E-B08F-58B3AF08BB6C

P2860

Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review

http://www.wikidata.org/entity/Q35584543

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Noncardiac vascular toxicities ...... s in advanced cancer: a review

@ast

Noncardiac vascular toxicities ...... s in advanced cancer: a review

@en

type

label

Noncardiac vascular toxicities ...... s in advanced cancer: a review

@ast

Noncardiac vascular toxicities ...... s in advanced cancer: a review

@en

prefLabel

Noncardiac vascular toxicities ...... s in advanced cancer: a review

@ast

Noncardiac vascular toxicities ...... s in advanced cancer: a review

@en

P1433

Q35584543-1A52D592-2063-45C0-A09C-E601CD53D0CC

P1476

Q35584543-D7688009-AC61-48BE-9EFC-37CC0DBE0862

P2093

Q35584543-02E3CA4A-D17C-4D68-9C5A-32B7BFEC2738

Q35584543-9508525E-71D4-4EB5-A894-683A57FDDC5D

Q35584543-ACE1EA71-C251-49D2-AA92-FA0EF82EB487

Q35584543-B57A4368-D50F-4AAF-82E7-11A20D87BD6A

Q35584543-BD1A552C-1EA8-4444-8F35-7EA10A6EF014

Q35584543-DB95013E-B6A1-429D-A1B1-D7088596FF8D

P2860

Q35584543-027ECF8B-C7B7-4AC2-A8D1-79B592838BFA

Q35584543-0C254CFD-EFCF-4508-9151-B40D22B38F32

Q35584543-0CB69C30-C4AC-40C1-A3EA-CD75D5845EB0

Q35584543-101B89F0-7E70-494C-99AD-5DFE3FEA896A

Q35584543-163BB8D1-21FF-4460-B177-A0160226C0F1

Q35584543-16E86A99-4AF6-4687-86B3-08CA65D22741

Q35584543-1AA2FCAD-879B-4633-86DD-0CF0583B12D0

Q35584543-1B3026A9-5B16-4CD7-9443-81DDBCDD3E03

Q35584543-1CDB1147-EB9F-4401-B1F5-F5B7D38A32CB

Q35584543-233C9A94-9451-4D2A-9565-787B4CADBDA3

P304

Q35584543-795CF8FC-1429-4A80-9476-CA5834AC72A1

P31

Q35584543-CBEF69B7-D919-4D6A-991F-36DA4F7ECEEC

P356

Q35584543-C55E8CFF-99E8-4FB5-B25F-DD518143CBC2

P433

Q35584543-7F48EC8D-A6CE-4BA8-BB7F-903297658E39

P478

Q35584543-28D61F2D-CF34-4BFB-B552-4B1CE8F7C29C

P577

Q35584543-AB1A8C46-9109-4458-836C-700B7F6CFD96

P5875

Q35584543-5B73555F-E31F-4EC8-AB27-F069AAA243AD

P698

Q35584543-116D8FF0-D5F5-4565-B6B0-6D6322E3AAE2

P921

Q35584543-3709ABEE-9E60-4E5A-AFB0-7F0FCD6B8CCC

P932

Q35584543-E9B874B1-2D0F-48A3-B885-92378370DF44

P356

THEONCOLOGIST.2010-0271

P1433

P1476

Noncardiac vascular toxicities ...... s in advanced cancer: a review

@en

P2093

Andrea Stringer

http://www.w3.org/2001/XMLSchema#string

Dorothy Keefe

http://www.w3.org/2001/XMLSchema#string

Joanne Bowen

http://www.w3.org/2001/XMLSchema#string

Meena Okera

http://www.w3.org/2001/XMLSchema#string

Rachel Gibson

http://www.w3.org/2001/XMLSchema#string

Thean Tan

http://www.w3.org/2001/XMLSchema#string

P2860

Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure

VEGF inhibition and renal thrombotic microangiopathy

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Sorafenib in advanced hepatocellular carcinoma

Incidence and management of bevacizumab-related toxicities in colorectal cancer

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer

Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

P304

432-444

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2010-0271

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2011-03-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50867748

http://www.w3.org/2001/XMLSchema#string

P698

21441297

http://www.w3.org/2001/XMLSchema#string

P921

P932

3228115

http://www.w3.org/2001/XMLSchema#string